查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929526

全球牙科抗發炎藥物市場（按藥物分類、給藥途徑、劑型、應用、最終用途和分銷管道分類）預測（2026-2032年）

Anti-inflammatory Drugs for Dental Market by Drug Class, Route Of Administration, Dosage Form, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，牙科抗發炎藥物市場價值將達到 16.5 億美元，到 2026 年將成長至 17.8 億美元，到 2032 年將達到 32.4 億美元，年複合成長率為 10.08%。

關鍵市場統計數據
基準年 2025 16.5億美元
預計年份：2026年 17.8億美元
預測年份 2032 32.4億美元
複合年成長率 (%) 10.08%

從策略角度概述了現代抗發炎療法如何透過在療效、安全性和配方方面的進步來重新定義手術全期牙科護理。

抗發炎療法是現代牙科診療的核心，可支持從常規拔牙到複雜牙周治療等多種診療程序。其作用不僅限於控制症狀，還能改善手術全期療效，減少發炎相關併發症，並維持患者術後恢復的舒適度。臨床醫生正日益將這些藥物整合到以安全性、快速康復和減少鴉片類藥物依賴性為優先考慮的多方面鎮痛通訊協定中。同時，製藥研發商和經銷商正致力於製劑創新和最佳化給藥途徑，以滿足不同的臨床需求。

不斷發展的臨床實踐、製劑創新、監管政策的明確性以及供應鏈的韌性如何共同重塑牙科抗炎療法的提供方式

牙科抗發炎治療領域正經歷著一場變革，其驅動力包括臨床實踐的改變、製劑創新以及監管的加強。臨床醫師正採用多管齊下的疼痛管理方法，結合局部和全身用藥，以最大限度地減少鴉片類藥物的使用，並加速功能恢復。這種臨床轉變促使生產商投資研發速效、標靶給藥系統，並將耐受性作為在競爭激烈的治療領域中脫穎而出的關鍵因素。

2025年美國關稅調整對牙科抗發炎療法籌資策略、業務地點和供應鏈合規性的影響

計劃於2025年生效的關稅政策和貿易措施正迫使牙科治療藥物的生產商和經銷商重新評估其採購、製造地和庫存策略。進口關稅的變化以及相關的合規義務加劇了全球供應鏈的成本敏感性，尤其是活性藥物成分和特殊輔料，這些成分通常需要跨境採購。為此，許多企業正在考慮近岸外包、雙重採購以及增加緩衝庫存，以降低時間風險並維持牙科診所和醫院的產品供應。

透過對藥物類別、劑型、通路、最終用戶和臨床應用進行綜合細分分析，將市場發展和分銷選擇連結起來。

關鍵細分趨勢揭示了不同藥物類別、給藥途徑、劑型、分銷管道、最終用戶和應用領域所帶來的不同的臨床和商業性機會。依藥物類別分類，市場結構包括皮質類固醇和非類固醇消炎劑（NSAIDs）。皮質類固醇的代表藥物包括地塞米松和潑尼松龍，而NSAIDs則包括Ibuprofen、酮洛芬和萘普生。這種治療方法的多樣性影響著牙科實踐中的處方模式和安全考量，臨床醫生會根據發炎的特徵、患者的合併症以及手術情況來選擇藥物。

影響臨床應用、監管協調、製造地和分銷策略的區域趨勢

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的需求促進因素、監管重點和分銷模式，每個地區都展現出獨特的臨床實踐和市場結構。在美洲，臨床上對門診牙科手術的關注以及對鴉片類藥物管理的日益重視，促使人們傾向於選擇口服和局部抗炎策略；而支付機制和採購框架則影響著通路的選擇和藥品目錄的收錄。

企業如何透過配方創新、證據產生、供應鏈強化和與臨床醫生合作來實現差異化，從而抓住牙科護理領域的機會

牙科抗發炎治療領域的競爭重點在於推進製劑科學、確保差異化的給藥機制以及最佳化生產和分銷網路。主要企業正投資於臨床證據的積累，以支持牙科特定適應症，並證明其在起效速度、持續時間和安全性方面優於傳統療法。製藥開發商和醫療設備製造商之間正在建立策略聯盟，以將局部和局部給藥技術的創新轉化為臨床可行的解決方案。

給經營團隊的實用建議：使研發、監管策略和供應鏈韌性與臨床需求和分銷實際情況保持一致

產業領導者可以透過將研發、監管和商業活動與臨床需求和供應鏈實際情況相結合，將當前趨勢轉化為競爭優勢。應優先開發臨床差異化的局部局部劑型，以減少全身暴露並促進快速恢復，同時確保針對牙科適應症的可靠安全性數據。此外，還應投資於比較臨床證據和實用工具，以幫助臨床醫生採用新的通訊協定並為採購決策的變更提供基礎。

採用透明的調查方法，結合臨床醫師訪談、監管審查、臨床文獻綜合和操作檢驗，得出基於證據的結論。

本研究整合了專家訪談、同儕審查的臨床文獻、監管指導文件和檢驗的營運情報，建構了強力的證據基礎。透過對牙科臨床醫生、處方箋負責人、採購經理和生產專家進行結構化訪談，收集了來自臨床、商業和供應鏈領域的實際觀點。這些定性見解與已發表的臨床研究和監管指導文件進行三角驗證，檢驗治療定位、安全性考慮因素和劑量偏好。

透過整合臨床重點、製劑創新、監管細微差別和營運彈性等因素，為策略決策提供支援。

牙科抗發炎治療藥物在臨床需求、製劑研發機會和供應鏈複雜性之間佔據著策略性性交匯點。臨床醫生越來越關注以病人安全、快速康復和減少對全身性鴉片類藥物依賴為優先的多方面治療方法，這推動了人們對局部用藥製劑和明確給藥通訊協定的興趣。同時，製造商和經銷商必須應對監管審查、關稅導致的供應鏈變化以及不斷變化的經銷管道趨勢，同時還要提供可在包括牙科診所、醫院和居家醫療機構在內的所有場所使用的差異化產品。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按藥物類別分類的牙科抗發炎藥物市場

  • 皮質類固醇
    • 地塞米松
    • 潑尼松龍
  • 非類固醇消炎劑
    • Ibuprofen
    • 酮洛芬
    • 萘普生

9. 按給藥途徑分類的牙科抗發炎藥物市場

  • 注射
  • 口服
  • 外用

第10章 按劑型分類的牙科抗發炎藥物市場

  • 凝膠
  • 注射
  • 漱口水
  • 藥片

第11章 按應用領域分類的牙科抗發炎藥物市場

  • 牙周疼痛
  • 術後疼痛
  • 術前疼痛

第12章 按最終用戶分類的牙科抗發炎藥物市場

  • 牙醫診所
  • 居家照護
  • 醫院

第13章 按分銷管道分類的牙科抗發炎藥市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 各地區牙科抗發炎藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 牙科抗發炎藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國牙科抗發炎藥物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國牙科抗發炎藥物市場

第18章 中國牙科抗發炎藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Church & Dwight Co. Inc.
  • Colgate-Palmolive Company
  • Dentsply Sirona Inc.
  • GlaxoSmithKline plc
  • Haleon plc
  • Henry Schein Inc.
  • Ivoclar Vivadent AG
  • Johnson & Johnson
  • Patterson Companies Inc.
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Septodont
  • Sunstar Suisse SA
  • VOCO GmbH
Product Code: MRR-0A38069517F6

The Anti-inflammatory Drugs for Dental Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.08%, reaching USD 3.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.24 billion
CAGR (%) 10.08%

A strategic overview of how contemporary anti-inflammatory therapies are redefining perioperative dental care through efficacy, safety, and formulation advances

Anti-inflammatory therapies are central to contemporary dental practice, supporting procedures from routine extractions to complex periodontal interventions. Their role extends beyond symptom suppression to shaping perioperative outcomes, reducing inflammation-driven complications, and supporting patient comfort during recovery. Clinicians increasingly integrate these agents into multimodal analgesia protocols that prioritize safety, rapid recovery, and reduced opioid reliance. Concurrently, pharmaceutical developers and distributors focus on formulation innovation and route optimization to meet diverse clinical needs.

Recent developments in pharmacology and formulation science have expanded the practical toolkit available to dental professionals. Topical gels and mouthwashes offer localized relief with minimized systemic exposure, while oral and injectable options permit dose flexibility and rapid onset for acute postoperative pain. Regulatory scrutiny of safety profiles, particularly related to systemic corticosteroids and nonsteroidal agents, has sharpened prescriber attention to indications, contraindications, and appropriate duration of therapy. As a result, decision makers across clinical, procurement, and product development functions are prioritizing evidence-based protocols that balance efficacy with tolerability.

This introduction frames anti-inflammatory agents not simply as adjuvants for symptomatic care but as strategic clinical tools that influence outcomes, patient satisfaction, and practice quality metrics. Understanding their therapeutic scope, administration routes, and implications for dental workflows sets the stage for deeper analysis of emerging trends, policy shifts, and supply chain dynamics addressed in subsequent sections.

How clinical practice evolution, formulation innovation, regulatory clarity, and supply chain resilience are jointly reshaping dental anti-inflammatory therapy provision

The landscape for dental anti-inflammatory therapeutics is undergoing transformative shifts driven by clinical practice changes, formulation innovation, and heightened regulatory focus. Clinicians are adopting multimodal pain management approaches that combine localized topical applications with systemic agents to minimize opioid exposure and accelerate functional recovery. This clinical pivot encourages manufacturers to invest in fast-acting, targeted delivery systems and to prioritize tolerability as a differentiator in crowded therapeutic categories.

Innovation in dosage forms has accelerated, with gels and mouthwashes being optimized for mucosal adhesion and sustained local effect, while injectable formulations are being refined for controlled release and lower systemic burden. Concurrently, adoption of digital health tools and tele-dentistry is altering how prescriptions are issued and monitored, creating demand for products that support remote adherence tracking and simplified administration regimens. Regulatory agencies are responding with clearer guidance on indications, labeling for dental-specific use cases, and safety monitoring for agents with systemic risks.

Supply chain resilience has become a competitive axis as manufacturers reassess sourcing strategies, quality assurance processes, and distribution partnerships to ensure continuity across channels. Together, these shifts are converging to create opportunities for clinically differentiated products, streamlined distribution models, and integrated care pathways that emphasize predictable, patient-centered outcomes.

Implications of the 2025 United States tariff adjustments on sourcing strategies, operational footprints, and supply chain compliance across dental anti-inflammatory therapies

Tariff policy and trade measures announced for implementation in 2025 are prompting manufacturers and distributors serving dental therapeutics to revisit sourcing, manufacturing footprint, and inventory strategies. Changes to import duties and related compliance obligations increase the cost sensitivity of global supply chains, particularly for active pharmaceutical ingredients and specialized excipients frequently sourced across borders. In response, many organizations are exploring near-shoring, dual-sourcing, and increased buffer inventories to mitigate timing risk and maintain product availability for dental practices and hospitals.

Beyond immediate cost implications, tariffs influence long-term strategic decisions about where to locate value-added activities such as formulation, packaging, and final assembly. Organizations reassessing their footprint are weighing the trade-offs between higher local operating costs and the benefits of reduced cross-border exposure, faster time-to-market, and simplified regulatory interactions. These trade-offs affect pricing strategies, distribution agreements, and the competitiveness of import-dependent product lines.

Regulatory compliance and customs documentation have become more prominent operational priorities, increasing demand for robust trade compliance teams and digital tracking systems that provide end-to-end visibility. For stakeholders in the dental therapeutics ecosystem, these adjustments underscore the necessity of integrated commercial and supply chain planning to preserve continuity of care for patients and to protect margins under shifting policy environments.

Comprehensive segmentation insights linking drug classes, delivery formats, channels, end users, and clinical applications to strategic development and distribution choices

Key segmentation dynamics reveal differentiated clinical and commercial opportunities across drug classes, administration routes, dosage forms, distribution channels, end users, and applications. Based on drug class, the landscape encompasses corticosteroids and nonsteroidal anti-inflammatory drugs; corticosteroids are further characterized by agents such as dexamethasone and prednisolone, while the nonsteroidal category includes ibuprofen, ketoprofen, and naproxen. This therapeutic diversity influences prescribing patterns and safety considerations in dental practice, with clinicians selecting agents according to inflammation profile, patient comorbidities, and procedural context.

Based on route of administration, treatment options span injectable, oral, and topical formats, each presenting unique advantages for onset of action, systemic exposure, and ease of use. Based on dosage form, the available modalities include gels, injections, mouthwashes, and tablets, and each form factor has implications for adherence, localized efficacy, and formulation challenges. Distribution channels range across hospital pharmacy, online pharmacy, and retail pharmacy, and channel selection impacts procurement workflows, stocking policies, and patient access.

End users for these therapies include dental clinics, home care settings, and hospitals, with each segment demanding different packaging, dosing instructions, and patient education materials. In terms of application, agents are utilized for periodontal pain, postoperative pain, and preoperative pain management, and clinical guidelines shape appropriate use across those scenarios. Taken together, these segmentation lenses provide actionable insight into where clinical needs, product design, and distribution strategy intersect to create opportunities for targeted innovation and value delivery.

Regional dynamics that determine clinical adoption, regulatory alignment, manufacturing footprint, and distribution strategies across global dental care geographies

Regional dynamics shape demand drivers, regulatory priorities, and distribution models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each exhibiting distinct clinical practices and market structures. In the Americas, clinical emphasis on ambulatory dental procedures and heightened focus on opioid stewardship steer preferences toward oral and topical anti-inflammatory strategies, while payer mechanisms and procurement frameworks influence channel adoption and formulary inclusion.

Europe, Middle East & Africa present a heterogeneous regulatory and clinical landscape in which national guidelines and varying reimbursement models affect adoption velocity for novel formulations and off-label dental indications. Regulatory harmonization efforts in certain economic blocs coexist with localized standards that require tailored compliance and labeling strategies. In contrast, the Asia-Pacific region is notable for rapid clinical adoption of novel dosage forms and an expanding manufacturing base that supports competitive production of both active ingredients and finished formulations, though regulatory pathways and quality expectations vary widely across jurisdictions.

These regional distinctions influence R&D prioritization, distribution partnerships, and supply chain design. Aligning product design and go-to-market approaches with regional clinical practices and regulatory realities enhances adoption potential and mitigates risks associated with cross-border distribution and differing standards of care.

How players are differentiating through formulation innovation, evidence generation, supply chain fortification, and clinician engagement to capture dental therapeutic opportunities

Competitive activity among companies engaged in dental anti-inflammatory therapeutics centers on advancing formulation science, securing differentiated delivery mechanisms, and optimizing manufacturing and distribution networks. Leading organizations are investing in clinical evidence generation to support dental-specific labeling and to demonstrate advantages in onset, duration, and safety relative to legacy options. Strategic collaborations between pharmaceutical developers and device manufacturers are emerging to convert topical and localized delivery innovations into practice-ready solutions.

Operationally, companies are strengthening their supply chain resilience through supplier diversification, quality systems modernization, and digital traceability to manage regulatory scrutiny and reduce exposure to single-source disruptions. On the commercial front, efforts to engage clinicians via targeted education, real-world evidence dissemination, and streamlined sample and procurement processes are increasingly important. Distribution strategies are also shifting, with some organizations expanding direct-to-clinic capabilities while others deepen partnerships with hospital and retail pharmacy networks to ensure product availability across care settings.

Collectively, these company-level moves emphasize differentiation through clinically meaningful innovation, disciplined operational execution, and collaborative approaches to market access that align with evolving dental practice patterns.

Actionable recommendations for executives to align R&D, regulatory strategy, and supply chain resilience with clinician needs and distribution realities

Industry leaders can convert current dynamics into competitive advantage by aligning R&D, regulatory, and commercial activities with clinical practice needs and supply chain realities. Prioritize development of clinically differentiated topical and localized delivery forms that reduce systemic exposure and support rapid recovery, while ensuring robust safety data tailored to dental indications. Simultaneously, invest in comparative clinical evidence and practical tools that help clinicians adopt new protocols and justify changes in procurement decisions.

Operationally, pursue supply chain de-risking through dual sourcing of critical ingredients, selective near-shoring, and enhanced digital compliance capabilities to navigate tariff and trade complexities. Collaborate with distribution partners to create flexible fulfillment models that span hospital pharmacy, online pharmacy, and retail pharmacy channels, and design packaging and dosing regimens optimized for dental clinics, hospitals, and home care environments. Finally, emphasize cross-functional alignment among medical affairs, regulatory, and commercial teams to translate evidence into clear labeling claims and adoption-ready educational programs that resonate with prescribers and procurement stakeholders.

These recommended actions will help organizations accelerate adoption, protect margins in changing policy contexts, and deliver therapies that align with contemporary priorities for efficacy, safety, and patient-centered recovery in dental care.

A transparent methodology combining clinician interviews, regulatory review, clinical literature synthesis, and operational validation to ensure evidence-driven conclusions

This research synthesizes primary expert interviews, peer-reviewed clinical literature, regulatory guidance documents, and validated operational intelligence to develop a robust evidence base. Primary insight was collected through structured interviews with dental clinicians, formulary managers, procurement leads, and manufacturing experts to capture practical perspectives across clinical, commercial, and supply chain domains. These qualitative inputs were triangulated with published clinical studies and regulatory guidance to validate therapeutic positioning, safety considerations, and administration preferences.

Operational data were drawn from industry-standard sources and validated vendor reports to map supply chain configurations, distribution channel dynamics, and manufacturing practices. Wherever possible, regulatory documentation and guidance from major health authorities were consulted to ensure that labeling considerations and safety monitoring requirements are accurately reflected. Throughout the methodology, data integrity checks, cross-source corroboration, and expert review were applied to ensure that conclusions reflect widely observed trends and actionable insights rather than isolated anecdotes.

The methodology emphasizes transparency in source types and analytic approaches and prioritizes clinician-validated interpretation of therapeutic roles, dosage forms, and route selection to ensure that recommendations are practicable within real-world dental settings.

Conclusion synthesizing clinical priorities, formulation innovation, regulatory nuance, and operational resilience to inform strategic decision making

Anti-inflammatory therapeutics for dental care occupy a strategic intersection of clinical need, formulation opportunity, and supply chain complexity. Clinicians are increasingly focused on multimodal approaches that prioritize patient safety, rapid recovery, and reduced reliance on systemic opioids, driving interest in localized formulations and well-defined administration protocols. Simultaneously, manufacturers and distributors must navigate regulatory scrutiny, tariff-induced supply chain shifts, and evolving channel dynamics to deliver differentiated products that are accessible across dental clinics, hospitals, and home care settings.

Success in this environment will favor organizations that couple clinical innovation with operational rigor: those that produce evidence-backed, dental-specific formulations and that execute resilient sourcing and distribution strategies. Clear alignment between medical affairs, regulatory, and commercial teams enhances the likelihood that new options reach patients efficiently and safely. Ultimately, the convergence of clinical priorities, regional regulatory nuance, and supply chain realities creates meaningful opportunities for stakeholders who can translate evidence into practice-ready solutions and reliably support clinicians across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-inflammatory Drugs for Dental Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Dexamethasone
    • 8.1.2. Prednisolone
  • 8.2. Nonsteroidal Anti-Inflammatory Drugs
    • 8.2.1. Ibuprofen
    • 8.2.2. Ketoprofen
    • 8.2.3. Naproxen

9. Anti-inflammatory Drugs for Dental Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Anti-inflammatory Drugs for Dental Market, by Dosage Form

  • 10.1. Gel
  • 10.2. Injection
  • 10.3. Mouthwash
  • 10.4. Tablet

11. Anti-inflammatory Drugs for Dental Market, by Application

  • 11.1. Periodontal Pain
  • 11.2. Postoperative Pain
  • 11.3. Preoperative Pain

12. Anti-inflammatory Drugs for Dental Market, by End User

  • 12.1. Dental Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Anti-inflammatory Drugs for Dental Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Anti-inflammatory Drugs for Dental Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-inflammatory Drugs for Dental Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-inflammatory Drugs for Dental Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-inflammatory Drugs for Dental Market

18. China Anti-inflammatory Drugs for Dental Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3M Company
  • 19.6. Church & Dwight Co. Inc.
  • 19.7. Colgate-Palmolive Company
  • 19.8. Dentsply Sirona Inc.
  • 19.9. GlaxoSmithKline plc
  • 19.10. Haleon plc
  • 19.11. Henry Schein Inc.
  • 19.12. Ivoclar Vivadent AG
  • 19.13. Johnson & Johnson
  • 19.14. Patterson Companies Inc.
  • 19.15. Pfizer Inc.
  • 19.16. Procter & Gamble Company
  • 19.17. Reckitt Benckiser Group PLC
  • 19.18. Septodont
  • 19.19. Sunstar Suisse S.A.
  • 19.20. VOCO GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY MOUTHWASH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PERIODONTAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY PREOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTI-INFLAMMATORY DRUGS FOR DENTAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)